恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价

吴艳琴; 沈黎俊; 于集虹; 孙玉山

doi:10.3969/j.issn.1001-5256.2017.05.011

恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价

DOI: 10.3969/j.issn.1001-5256.2017.05.011

1. 新疆巴州人民医院感染性疾病科
2. 新疆巴州人民医院CT室
3. 新疆巴州人民医院医学超声科

基金项目:

春雨工程感染科专项科研基金(2014-05)；

详细信息

中图分类号: R512.62;R575
计量
- 文章访问数: 2811
- HTML全文浏览量: 51
- PDF下载量: 416
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Clinical effect of entecavir in treatment of chronic hepatitis B complicated by hepatic steatosis

Department of Infectious Diseases, Bazhou People′s Hospital

Research funding:

摘要

摘要:
目的探讨慢性乙型肝炎（CHB）合并肝脂肪变患者经恩替卡韦抗病毒治疗后的效果。方法纳入新疆巴州人民医院2014年6月-2015年6月就诊的HBe Ag阳性CHB患者164例,根据肝小叶内肝脂肪变的肝细胞数占总肝细胞数的比例将其分为3组:脂肪变肝细胞占比<5%（对照组,89例）,脂肪变肝细胞占比5%30%（a组,43例）,脂肪变肝细胞占比>30%组（B组,32例）。患者均给予恩替卡韦治疗。检测患者治疗前和治疗后24、48周血清病毒学指标和肝功能指标变化。计量资料组间比较采用单因素方差分析,进一步两两比较采用Bonferroni法;计数资料组间比较采用χ2检验。结果肝脂肪变不影响恩替卡韦治疗24周时的病毒学应答（P>0.05）,但恩替卡韦治疗48周时,B组HBe Ag阴转率（34.4%vs 60.2%）和HBV DNA阴转率（40.6%vs67.4%）均明显低于对照组,差异具有统计学意义（P值分别为0.012和0.008）;恩替卡韦治疗24和48周时,A组、B组的ALT复常率明显低于对照组,差异均有统计学意义（A组:P值分别为0....
- 肝炎,乙型,慢性 /
- 脂肪肝 /
- 恩替卡韦 /
- 治疗结果
Abstract:
Objective To investigate the effect of antiviral therapy with entecavir in the treatment of chronic hepatitis B (CHB) complicated by hepatic steatosis.Methods A total of 164 HBe Ag-positive CHB patients who visited Bazhou People's Hospital from June 2014 to June2015 were enrolled, and according to the percentage of hepatocytes with steatosis in the hepatic lobules in all hepatocytes, they were divided into control group (<5% 43="" 89="" of="" hepatocytes="" with="" group="" a="" and="" b="">30% of hepatocytes with steatosis, 32 patients) .All patients were treated with entecavir.The serum virological parameters and liver function parameters were measured before treatment and at weeks 24 and 48 of treatment.A one-way analysis of variance was used for comparison of continuous data between groups, and the Bonferroni method was used for comparison between any two groups;the chi-square test was used for comparison of categorical data between groups.Results Hepatic steatosis did not affect the virologic response at week 24 of entecavir treatment (P>0.05) .However at week 48 of entecavir treatment, compared with the control group, group B had significantly lower HBe Ag clearance rate (34.4% vs 60.2%, P=0.012) and HBV DNA clearance rate (40.6% vs 67.4%, P=0.008) .At weeks 24 and 48 of entecavir treatment, compared with the control group, groups A and B had a significantly lower alanine aminotransferase normalization rate than the control group (group A:P=0.013 and 0.001;group B:P=0.001 and P<0.001) and significantly higher levels of aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase (group A:P24<0.001, P24=0.031, and P24=0.001, P48<0.001, P48=0.021, and P48<0.001;group B:P24<0.001, P24=0.028, and P24=0.001, P48<0.001, P48=0.017, P48<0.001) .conclusion="" a="" percentage="" of="" hepatocytes="" with="" steatosis="">30% is associated with the reduction in virologic response at week48 of entecavir treatment.Hepatic steatosis affects the biochemical response in CHB patients at weeks 24 and 48 of entecavir treatment.
- hepatitis B, chronic /
- fatty liver /
- entecavir /
- treatment outcome

HTML全文

参考文献(17)

[1]BOONSTRA A, WOLTMAN AM, JANSSEN HL.Immunology o hepatitis B and hepatitis C virus infections[J].Best Pract Res Clin Gastroenterol, 2008, 22 (6) :1049-1061.

[2]PENG D, HAN Y, DING H, et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J].J Gastroenterol Hepatol, 2008, 23 (7 Pt 1) :1082-1088.

[3]MACHADO MV, OLIVEIRA AG, CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients[J].J Gastroenterol Hepatol, 2011, 26 (9) :1361-1367.

[4]SHI JP, FAN JG, WU R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol, 2008, 23 (9) :1419-1425.

[5]LIU SE, HAO MN, REN YN, et al.Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response[J].Chin J Hepatol, 2015, 23 (5) :333-338. (in Chinese) 刘淑娥, 郝美娜, 任亚楠, 等.慢性乙型肝炎患者合并脂肪肝导致单纯抗病毒治疗生物化学应答不佳诊疗分析[J].中华肝脏病杂志, 2015, 23 (5) :333-338.

[6]CINDORUK M, KARAKAN T, UNAL S.Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection[J].J Clin Gastroenterol, 2007, 41 (5) :513-517.

[7] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[8]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[9]KIM KH, SHIN HJ, KIM K, et al.Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ[J].Gastroenterology, 2007, 132 (5) :1955-1967.

[10]ZHENG RD, CHEN JN, ZHUANG QY, et al.Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis[J].Int J Med Sci, 2013, 10 (5) :641-646.

[11]ZHENG RD, XU CR, JIANG L, et al.Predictors of hepatic steatosis in HBe Ag-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis[J].Int J Med Sci, 2010, 7 (5) :272-277.

[12]ATES F, YALNIZ M, ALAN S.Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B[J].World J Gastroenterol, 2011, 17 (40) :4517-4522.

[13]SHI JP, LU L, QIAN JC, et al.Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B[J].Chin J Hepatol, 2012, 20 (4) :285-288. (in Chinese) 施军平, 陆璐, 钱建成, 等.肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J].中华肝脏病杂志, 2012, 20 (4) :285-288.

[14]JIN X, CHEN YP, YANG YD, et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLo S One, 2012, 7 (3) :e34198.

[15]LECLERCQ I, HORSMANS Y, DESAGER JP, et al.Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation[J].JHepatol, 1998, 28 (3) :410-416.

[16]WU L, PAREKH VV, GABRIEL CL, et al.Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice[J].Proc Nati Acad U S A, 2012, 109 (19) :e1143-e1152.

[17]KANURI G, LADURNER R, SKIBOVSKAYA J, et al.Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease[J].Liver Int, 2015, 35 (2) :562-568.

施引文献

资源附件(0)

访问统计